Ocrelizumab versus placebo in primary progressive multiple sclerosis Montalban X, Hauser SL, Kappos L, et al; ORATORIO Clinical Investigators. N Engl J Med 2016; doi: 10.1056/NEJMoa1606468 (Epub ahead of print). Abstract BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a […]
Neurochecklists now contains >1600 checklists on all aspects of neurology. Many checklists come to the rescue only to fill a knowledge gap. Most neurochecklists however address important practical questions or outline pragmatic steps in managing neurological disorders. To illustrate, below is a selection of 40 handy neurochecklists *** Anticoagulants: bridging therapy for surgery Antiepileptic drugs (AEDs): choice […]
Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial Schapira AH, Fox SH, Hauser RA, et al. JAMA Neurol 2016; doi: 10.1001/jamaneurol.2016.4467 (Epub ahead of print). Abstract IMPORTANCE: Although levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its […]
Dissection is an increasingly recognized cause of ischemic stroke, which occurs spontaneously or after trauma, in relatively young patients. We hypothesized that there might be a predisposing factor weakening the vascular wall and […]
The Neurology Lounge started in July 2015 and it is now well into its 2nd year. 2016 was the first complete 12-month calendar period, and during this time the blog received about 25,000 visits and just under 40,000 views.
There were visitors from >150 countries around the world with the United States recording the most visits at just under 15,000, followed closely by the United Kingdom with about 5,000. There were >1,000 visitors each from Canada, Australia, Spain and India. Engagement however remains disappointingly low with only 117 comments and 67 likes.
Some topics attracted more interest than others, sometimes surprisingly so. Below is the countdown of the 15 most viewed posts on The Neurology Lounge in 2016.
Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial Ferreira JJ, Lees A, Rocha JF, et al; Bi-Park 1 investigators. Lancet Neurol 2016; 15:154-165 Abstract BACKGROUND: Opicapone is a novel, once-daily, potent third-generation catechol-O-methyltransferase inhibitor. We aimed to assess the safety and efficacy of […]
Neurochecklists is in a continuous process of improvement and enhancement. To do so, it keeps up with the latest neurology articles and reviews, and stays on top of the latest guidelines and current trends. And these are churned out by the minute. In the Neurochecklists spirit of comprehensiveness and recency, below are 10 recent checklists which have been revised […]